Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp is experiencing significant growth in its plasma and hospital segments, with plasma sales benefiting from market share gains and increasing collection volumes, particularly with an expected organic growth rate of 14-17% excluding CSL for FY26. The company's financial health is also reflected in its improved profitability, as evidenced by a 380 basis point increase in gross margin and a 250 basis point increase in operating margin year-over-year. Furthermore, Haemonetics projects free cash flow for FY26 to be between $170 million and $210 million, demonstrating a positive upward revision from previous estimates and indicating strong operational cash generation.

Haemonetics Corp. reported a significant organic decline in plasma sales by 10.1%, indicative of ongoing challenges in sustaining growth within its key segments, particularly as organic growth slowed further to a 1.8% decrease in F2Q26. The company's guidance for FY2026 reflects a projected decline of 1% to 4% year-over-year, raising concerns regarding its ability to achieve previous growth targets, particularly with the downward revision of expected organic hospital growth from 8-11% to 4-7%. Additionally, the anticipated ongoing decline in the Interventional Technologies segment is expected to negatively impact gross margins, further compounding concerns around Haemonetics's operating performance and earnings projections which are now below consensus estimates.